-

Shareholder Alert: Robbins LLP Announces FirstEnergy Corp. (FE) Accused of Misleading Shareholders

SAN DIEGO & AKRON, Ohio--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of FirstEnergy Corp. (NYSE: FE) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 21, 2017 and July 21, 2020. FirstEnergy generates, transmits, and distributes electricity in the United States.

If you suffered a loss as a result of FirstEnergy's misconduct, click here.

FirstEnergy Corp. (FE) Accused of Engaging in an Illicit Bribery Scheme

According to the complaint, at the end of fiscal 2016, FirstEnergy reported a weak energy market, poor forecast demand, and hundreds of millions of dollars in losses. To alleviate investor concern, FirstEnergy stated in its annual report for 2016 that it intended to pursue "legislative or regulatory solutions" to remedy its dismal financial prospects. However, FirstEnergy failed to disclose that these solutions included an illicit campaign that funneled tens of millions of dollars to state lawmakers, including Ohio House Speaker Larry Householder, issuing misleading messages on media platforms, and illegally thwarting a citizen's ballot initiative to secure the votes for passage of Ohio House Bill 6 ("HB6"), which provided a $1.3 billion ratepayer-funded bailout to keep FirstEnergy's nuclear facilities in operation. On July 21, 2020, federal agents announced the arrest of Householder and four other individuals, including a prominent FirstEnergy lobbyist in connection with a $60 million racketeering and bribery scheme. The criminal complaint described FirstEnergy's extensive bribery scheme and corruptive tactics to ensure the passage of HB6 as "the largest bribery, money-laundering scheme" in Ohio history. On this news, the price of FirstEnergy stock plummeted, trading as low as $22.85 per share on July 22, 2020, representing a 45% decline from its closing price of $41.26 per share on July 20, 2020.

FirstEnergy Corp. (FE) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against FirstEnergy settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Al...

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit...

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...
Back to Newsroom